Macro Finance
Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy
CNBC Business·November 18, 2026·1 min read
Hims & Hers, the telehealth company, has launched new peptide treatments, offering compounded forms of sermorelin, glutathione, NAD+, vitamin B-12, and L-carnitine. None of these are FDA-approved. The company admits there's more to learn about their efficacy, but is moving forward with the products to meet consumer demand.
Read at CNBC BusinessDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.
